IL6 and COVID-19: Combined with findings from the RECOVERY, ACTIV4 and REMAP-CAP trials, GARDEN adds to the evidence that antiplatelet drugs (either marketed or not) may remain inactive on non-conventional platelet activation pathways (e.g. viral proteins, immune complexes, the low affinity Fc receptor Fcγ RIIA, complement fractions or IL6 in COVID-19) [36].